ClinicalTrials.gg
CompletedNCT03444467Updated Sep 5, 2018

First Research Study to Compare a Possible New Medicine NNC9204-1513 to the Medicine Glucagon, in Healthy People.

A Phase 1 interventional study of NNC9204-1513 and Glucagon in Diabetes, Diabetes Mellitus, Type 1 and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-09-05.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was May 2018, 8 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 642 studies in Diabetes Mellitus by Novo Nordisk A/S — 2 open to participants now, 3 under way, 1 of them phase 3. Diabetes Mellitus · Novo Nordisk A/S.

Enrollment
366th of 494
36 · median 87
Started
2018
with 4 others
Phase 1
206 of 642
1 open now
Registered
635th of 642
by date

Among the 642 studies in Diabetes Mellitus by Novo Nordisk A/S, this one is the 366th largest by enrollment of the 494 interventional ones that give a count, is one of 5 that started in 2018, is one of 206 in phase 1, and was the 635th registered.

Diabetes Mellitus

8,294 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

2 of the 642 studies in Diabetes Mellitus by Novo Nordisk A/S are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 359 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 642 studies in Diabetes Mellitus by Novo Nordisk A/S, or all of them as a file.
02

Study summary

The study is comparing the new medicine NNC9204-1513 with a standard therapy of glucagon (GlucaGen®). This is the first time NNC9204-1513 is given to humans.

Participants will either receive NNC9204-1513 or GlucaGen® - which treatment you get is decided by chance (like flipping a coin). Neither the participant nor the study doctor will know which study medicine (NNC9204-1513 or GlucaGen®) the participant is receiving (double -blinding). In case of emergency, this information will be readily available.

NNC9204-1513 is a new medicine for rescue treatment of severe low blood sugar and currently not available on the market (doctors cannot prescribe this medicine). The participant will receive two or three single injections below the skin. One injection will contain NNC9204-1513 or GlucaGen®. The other injection will include placebo - this is a product that looks like the actual study drug but without any active ingredients. If a third injection is given, this will contain NNC9204-1513 or placebo. NNC9204-1513 and GlucaGen® will be given using different devices and volumes. In order to mask these external differences, a "double dummy" approach will be used, that means when you get either of the study medicine (NNC9204-1513 or GlucaGen®) you will get another injection which contains no medicine called 'placebo' (it will not have any effect on the body). Dependent on the injection volume to be administered, injections are given by either syringe with needle or an injection pen (NovoPen Echo®). The study will last for up to 39 days.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 1
  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male, aged 18 -55 years (both inclusive), at the time of signing
  • (BMI) between 18.5 and 28.0 kg/sqm (both inclusive)
  • Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, and clinical laboratory tests performed during the screening visit, as judged by the investigator

Exclusion criteria

Exclusion Criteria:

  • Any disorder which in the investigator's opinion might jeopardise subject's safety, evaluation of results, or compliance with the protocol
  • Smoker (defined as a subject who is smoking at least one cigarette or equivalent daily) who is not able or willing to refrain from smoking and use of nicotine substitute products during the inpatient period
  • Any blood draw in excess of 25 mL in the past month, or donation of blood or plasma in excess of 400 mL within the 3 months preceding screening
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    NNC9204-1513

    Participants will receive increasing doses of NNC9204-1513.

    Drug: NNC9204-1513 · Drug: Placebo

  • Active comparator
    Glucagon

    Participants will receive a single fixed dose of glucagon.

    Drug: Glucagon · Drug: Placebo

Interventions

  • DrugNNC9204-1513

    Participants will receive NNC9204-1513 subcutaneous (s.c., in to a skin fold on the stomach) injection as single increasing doses of 0.01 mg, 0.04 mg, 0.10 mg, 0.25 mg, 0.50 mg, 1.0 mg or 2.0 mg. Each participant will only be given one dose. Dose escalation will proceed to the next planned dose level if there are no safety concerns raised by the investigator or by the trial safety group.

  • Participants will receive single dose of 1 mg glucagon s.c. injection.

    Also known as: GlucaGen®

  • DrugPlacebo

    Participants will receive single dose of placebo (for double dummy injections).

06

What researchers measure

Primary outcomes

  1. Number of treatment emergent adverse events (TEAEs)

    Count of events

    Time frame: from time of dosing (day 1) to completion of the safety follow-up visit (day 8)

Secondary outcomes

  1. Change from baseline in haematology

    Time frame: baseline (day 1), follow-up visit (day 8)

  2. Change from baseline in biochemistry

    Time frame: baseline (day 1), follow-up visit (day 8)

  3. Change from baseline in fibrinogen

    measured in g/L

    Time frame: baseline (day 1), follow-up visit (day 8)

  4. Change from baseline in lipids

    Time frame: baseline (day 1), follow-up visit (day 8)

  5. Change from baseline in glucose metabolism

    Time frame: baseline (day 1), follow-up visit (day 8)

  6. Change from baseline in hormones

    Time frame: baseline (day 1), follow-up visit (day 8)

  7. Change from baseline in urine dipstick parameter

    Time frame: baseline (day 1), follow-up visit (day 8)

  8. Change from baseline in systolic- and diastolic blood pressure

    Measured in mm Hg

    Time frame: baseline (day 1), follow-up visit (day 8)

  9. Change from baseline in body temperature

    Time frame: baseline (day 1), follow-up visit (day 8)

  10. Change from baseline in respiration rate

    Time frame: baseline (day 1), follow-up visit (day 8)

  11. Change from baseline in 12-lead electrocardiogram (ECG) heart rate

    Time frame: baseline (day 1), follow-up visit (day 8)

  12. Change from baseline in 12-lead ECG (RR interval)

    Time frame: baseline (day 1), follow-up visit (day 8)

  13. Change from baseline in 12-lead ECG (PR interval)

    Time frame: baseline (day 1), follow-up visit (day 8)

  14. Change from baseline in 12-lead ECG (QRS interval)

    Time frame: baseline (day 1), follow-up visit (day 8)

  15. Change from baseline in 12-lead ECG (QT interval)

    Time frame: baseline (day 1), follow-up visit (day 8)

  16. Change from baseline in 12-lead ECG (QTc intervals [Fridericia])

    QT interval corrected for heart rate by Fridericia's formula

    Time frame: baseline (day 1), follow-up visit (day 8)

  17. Change from baseline in Physical examination

    Time frame: baseline (day 1), follow-up visit (day 8)

  18. Incidence of injection site reactions

    Time frame: After administration of the trial products (day 1) until completion of the post-treatment follow-up visit (day 8).

  19. AUC0-15min,SD, area under the plasma concentration time curve

    Time frame: 0 to 15 minutes after single dose

  20. t1/2,SD, terminal half-life

    Time frame: Measured for 24 hours after administration of a single s.c. dose

  21. Onset of appearance

    Time from trial product administration until first time plasma concentration ≥ lower limit of quantification (LLOQ)

    Time frame: Measured for 24 hours after administration of a single s.c. dose

  22. AUCPG,0-15min,SD, area under the plasma glucose time curve

    Time frame: 0 to 15 minutes after single dose

  23. ΔPG0-15min,SD, Increase in plasma glucose concentration from 0 to 15 minutes

    Calculated as: Plasma glucose concentration at 15 minutes after single dose minus plasma glucose concentration at 0 minute

    Time frame: 0 to 15 minutes after single dose

  24. Change from baseline in 12-lead ECG (overall evaluation)

    Time frame: baseline (day 1), follow-up visit (day 8)

  25. Change from baseline in prothrombin time

    measured in seconds

    Time frame: baseline (day 1), follow-up visit (day 8)

  26. Change from baseline in Activated Partial Thromboplastin time (APTT)

    measured in seconds

    Time frame: baseline (day 1), follow-up visit (day 8)

07

Study locations

1 site
  • Novo Nordisk Investigational Site
    Berlin, 10117, Germany
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · www.novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in May 2018, 3 months.

Of 171 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 10. This study's 3 months is below that.

Counting every sponsor, half of 247 studies reached it within 7 months; a quarter within 3 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2018
First posted
Feb 23, 2018
StartActual
Feb 5, 2018
Primary completionActual
May 24, 2018
CompletionActual
May 24, 2018
Last update
Sep 5, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03444467
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Feb 23, 2018
Start date
Feb 5, 2018
Primary completion
May 24, 2018
Completion
May 24, 2018
Last update
Sep 5, 2018

Study contacts

Clinical Reporting Anchor and Disclosure (1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion